FDA Approves Genentech’s Alecensa as First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Genentech, announced that the US FDA has approved Alecensa® for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, as detected by an FDA-approved test.